---
document_datetime: 2025-11-23 11:39:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/onsenal.html
document_name: onsenal.html
version: success
processing_time: 0.0989454
conversion_datetime: 2025-12-27 14:19:40.060871
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Onsenal

[RSS](/en/individual-human-medicine.xml/66061)

##### Withdrawn

This medicine's authorisation has been withdrawn

celecoxib

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Onsenal](#more-information-on-onsenal-599)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 17 October 2003 the European Commission issued a marketing authorisation under exceptional circumstances valid throughout the European Union for the medicinal product Onsenal (celecoxib) for the reduction of the number of adenomatous intestinal polyps in familial adenomatous polyposis, as an adjunct to surgery and further endoscopic surveillance.

A marketing authorisation under exceptional circumstances may be granted if the applicant is unable to provide comprehensive data on the efficacy and safety of the medicine for which authorisation is being sought, due to the rarity of the condition it is intended for, limited scientific knowledge in the area concerned, or ethical considerations involved in the collection of such data. Therefore, it will normally be subject to specific obligation(s) during its life-cycle.

At the time of marketing authorisation for Onsenal, the applicant was given a specific obligation to provide further data on its efficacy and safety. The marketing authorisation holder (MAH) for Onsenal was Pfizer Limited. The European Commission was notified by a letter dated 10 March 2011 of the MAH's decision to voluntarily withdraw the marketing authorisation for Onsenal.

The reason given was that the MAH has not yet been able to provide the additional data required to fulfil its specific obligation, as a result of slow enrolment in an ongoing clinical trial. Onsenal was marketed in all EU countries except for Bulgaria, Hungary, Malta, Romania and Slovenia. At the time of the withdrawal, Onsenal was undergoing the 8th annual reassessment by the CHMP.

On the basis of the documentation submitted, the CHMP was of the view that the specific obligation necessary to maintain the marketing authorisation had not been fulfilled. The CHMP, therefore, requested supplementary information to be provided in order to confirm that the benefits associated with the use of Onsenal in the treatment of familial adenomatous polyposis still outweigh its risks.

On 28 March 2011 the European Commission issued a decision to withdraw the marketing authorisation for Onsenal.

Pursuant to this decision the European Public Assessment Report for Onsenal is updated to reflect that the marketing authorisation is no longer valid.

Onsenal : EPAR - Summary for the public

English (EN) (268.74 KB - PDF)

**First published:** 09/11/2009

**Last updated:** 06/04/2011

[View](/en/documents/overview/onsenal-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-807)

български (BG) (413.76 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/bg/documents/overview/onsenal-epar-summary-public_bg.pdf)

español (ES) (330.59 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/es/documents/overview/onsenal-epar-summary-public_es.pdf)

čeština (CS) (382.99 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/cs/documents/overview/onsenal-epar-summary-public_cs.pdf)

dansk (DA) (329.69 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/da/documents/overview/onsenal-epar-summary-public_da.pdf)

Deutsch (DE) (330.69 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/de/documents/overview/onsenal-epar-summary-public_de.pdf)

eesti keel (ET) (328.93 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/et/documents/overview/onsenal-epar-summary-public_et.pdf)

ελληνικά (EL) (419.21 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/el/documents/overview/onsenal-epar-summary-public_el.pdf)

français (FR) (330.54 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/fr/documents/overview/onsenal-epar-summary-public_fr.pdf)

italiano (IT) (330.09 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/it/documents/overview/onsenal-epar-summary-public_it.pdf)

latviešu valoda (LV) (387.05 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/lv/documents/overview/onsenal-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (355.07 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/lt/documents/overview/onsenal-epar-summary-public_lt.pdf)

magyar (HU) (378.98 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/hu/documents/overview/onsenal-epar-summary-public_hu.pdf)

Malti (MT) (398.93 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/mt/documents/overview/onsenal-epar-summary-public_mt.pdf)

Nederlands (NL) (328.95 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/nl/documents/overview/onsenal-epar-summary-public_nl.pdf)

polski (PL) (384.61 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/pl/documents/overview/onsenal-epar-summary-public_pl.pdf)

português (PT) (330 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/pt/documents/overview/onsenal-epar-summary-public_pt.pdf)

română (RO) (354.09 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/ro/documents/overview/onsenal-epar-summary-public_ro.pdf)

slovenčina (SK) (382.91 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/sk/documents/overview/onsenal-epar-summary-public_sk.pdf)

slovenščina (SL) (378.8 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/sl/documents/overview/onsenal-epar-summary-public_sl.pdf)

Suomi (FI) (329.99 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/fi/documents/overview/onsenal-epar-summary-public_fi.pdf)

svenska (SV) (329.33 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/sv/documents/overview/onsenal-epar-summary-public_sv.pdf)

## Product information

Onsenal : EPAR - Product Information

English (EN) (701.2 KB - PDF)

**First published:** 09/11/2009

**Last updated:** 06/04/2011

[View](/en/documents/product-information/onsenal-epar-product-information_en.pdf)

[Other languages (23)](#file-language-dropdown-204)

български (BG) (1.75 MB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/bg/documents/product-information/onsenal-epar-product-information_bg.pdf)

español (ES) (808.39 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/es/documents/product-information/onsenal-epar-product-information_es.pdf)

čeština (CS) (1.27 MB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/cs/documents/product-information/onsenal-epar-product-information_cs.pdf)

dansk (DA) (787.42 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/da/documents/product-information/onsenal-epar-product-information_da.pdf)

Deutsch (DE) (828.55 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/de/documents/product-information/onsenal-epar-product-information_de.pdf)

eesti keel (ET) (791.7 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/et/documents/product-information/onsenal-epar-product-information_et.pdf)

ελληνικά (EL) (1.87 MB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/el/documents/product-information/onsenal-epar-product-information_el.pdf)

français (FR) (850.82 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/fr/documents/product-information/onsenal-epar-product-information_fr.pdf)

íslenska (IS) (800.8 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/is/documents/product-information/onsenal-epar-product-information_is.pdf)

italiano (IT) (811.86 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/it/documents/product-information/onsenal-epar-product-information_it.pdf)

latviešu valoda (LV) (1.35 MB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/lv/documents/product-information/onsenal-epar-product-information_lv.pdf)

lietuvių kalba (LT) (810.35 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/lt/documents/product-information/onsenal-epar-product-information_lt.pdf)

magyar (HU) (1.39 MB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/hu/documents/product-information/onsenal-epar-product-information_hu.pdf)

Malti (MT) (1.46 MB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/mt/documents/product-information/onsenal-epar-product-information_mt.pdf)

Nederlands (NL) (803.39 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/nl/documents/product-information/onsenal-epar-product-information_nl.pdf)

norsk (NO) (778.55 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/no/documents/product-information/onsenal-epar-product-information_no.pdf)

polski (PL) (1.44 MB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/pl/documents/product-information/onsenal-epar-product-information_pl.pdf)

português (PT) (827.81 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/pt/documents/product-information/onsenal-epar-product-information_pt.pdf)

română (RO) (821.02 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/ro/documents/product-information/onsenal-epar-product-information_ro.pdf)

slovenčina (SK) (1.4 MB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/sk/documents/product-information/onsenal-epar-product-information_sk.pdf)

slovenščina (SL) (1.27 MB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/sl/documents/product-information/onsenal-epar-product-information_sl.pdf)

Suomi (FI) (802.87 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/fi/documents/product-information/onsenal-epar-product-information_fi.pdf)

svenska (SV) (767.89 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

06/04/2011

[View](/sv/documents/product-information/onsenal-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0028 28/03/2011

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

## Product details

Name of medicine Onsenal Active substance celecoxib International non-proprietary name (INN) or common name celecoxib Therapeutic area (MeSH) Adenomatous Polyposis Coli Anatomical therapeutic chemical (ATC) code L01XX33

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Onsenal is indicated for the reduction of the number of adenomatous intestinal polyps in familial adenomatous polyposis (FAP), as an adjunct to surgery and further endoscopic surveillance (see section 4.4).

The effect of Onsenal-induced reduction of polyp burden on the risk of intestinal cancer has not been demonstrated (see sections 4.4 and 5.1)

## Authorisation details

EMA product number EMEA/H/C/000466

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Marketing authorisation holder

Pfizer Limited

Ramsgate Road

Marketing authorisation issued 17/10/2003 Withdrawal of marketing authorisation 28/11/2008 Revision 13

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Onsenal : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (326.99 KB - PDF)

**First published:** 09/11/2009

**Last updated:** 06/04/2011

[View](/en/documents/procedural-steps-after/onsenal-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Onsenal : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (307.01 KB - PDF)

**First published:** 15/11/2005

**Last updated:** 06/04/2011

[View](/en/documents/steps-after-cutoff/onsenal-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

Onsenal : EPAR - Scientific Conclusion

English (EN) (297.46 KB - PDF)

**First published:** 15/11/2005

**Last updated:** 06/04/2011

[View](/en/documents/scientific-conclusion/onsenal-epar-scientific-conclusion_en.pdf)

[Other languages (18)](#file-language-dropdown-136)

español (ES) (298.99 KB - PDF)

**First published:**

15/11/2005

**Last updated:**

06/04/2011

[View](/es/documents/scientific-conclusion/onsenal-epar-scientific-conclusion_es.pdf)

čeština (CS) (342.77 KB - PDF)

**First published:**

15/11/2005

**Last updated:**

06/04/2011

[View](/cs/documents/scientific-conclusion/onsenal-epar-scientific-conclusion_cs.pdf)

dansk (DA) (303.87 KB - PDF)

**First published:**

15/11/2005

**Last updated:**

06/04/2011

[View](/da/documents/scientific-conclusion/onsenal-epar-scientific-conclusion_da.pdf)

Deutsch (DE) (306.78 KB - PDF)

**First published:**

15/11/2005

**Last updated:**

06/04/2011

[View](/de/documents/scientific-conclusion/onsenal-epar-scientific-conclusion_de.pdf)

eesti keel (ET) (297.18 KB - PDF)

**First published:**

15/11/2005

**Last updated:**

06/04/2011

[View](/et/documents/scientific-conclusion/onsenal-epar-scientific-conclusion_et.pdf)

ελληνικά (EL) (382.68 KB - PDF)

**First published:**

15/11/2005

**Last updated:**

06/04/2011

[View](/el/documents/scientific-conclusion/onsenal-epar-scientific-conclusion_el.pdf)

français (FR) (303.88 KB - PDF)

**First published:**

15/11/2005

**Last updated:**

06/04/2011

[View](/fr/documents/scientific-conclusion/onsenal-epar-scientific-conclusion_fr.pdf)

italiano (IT) (296.88 KB - PDF)

**First published:**

15/11/2005

**Last updated:**

06/04/2011

[View](/it/documents/scientific-conclusion/onsenal-epar-scientific-conclusion_it.pdf)

latviešu valoda (LV) (363.8 KB - PDF)

**First published:**

15/11/2005

**Last updated:**

06/04/2011

[View](/lv/documents/scientific-conclusion/onsenal-epar-scientific-conclusion_lv.pdf)

lietuvių kalba (LT) (334.44 KB - PDF)

**First published:**

15/11/2005

**Last updated:**

06/04/2011

[View](/lt/documents/scientific-conclusion/onsenal-epar-scientific-conclusion_lt.pdf)

magyar (HU) (342.38 KB - PDF)

**First published:**

15/11/2005

**Last updated:**

06/04/2011

[View](/hu/documents/scientific-conclusion/onsenal-epar-scientific-conclusion_hu.pdf)

Nederlands (NL) (301.31 KB - PDF)

**First published:**

15/11/2005

**Last updated:**

06/04/2011

[View](/nl/documents/scientific-conclusion/onsenal-epar-scientific-conclusion_nl.pdf)

polski (PL) (356.38 KB - PDF)

**First published:**

15/11/2005

**Last updated:**

06/04/2011

[View](/pl/documents/scientific-conclusion/onsenal-epar-scientific-conclusion_pl.pdf)

português (PT) (305.83 KB - PDF)

**First published:**

15/11/2005

**Last updated:**

06/04/2011

[View](/pt/documents/scientific-conclusion/onsenal-epar-scientific-conclusion_pt.pdf)

slovenčina (SK) (343.33 KB - PDF)

**First published:**

15/11/2005

**Last updated:**

06/04/2011

[View](/sk/documents/scientific-conclusion/onsenal-epar-scientific-conclusion_sk.pdf)

slovenščina (SL) (342.21 KB - PDF)

**First published:**

15/11/2005

**Last updated:**

06/04/2011

[View](/sl/documents/scientific-conclusion/onsenal-epar-scientific-conclusion_sl.pdf)

Suomi (FI) (300.62 KB - PDF)

**First published:**

15/11/2005

**Last updated:**

06/04/2011

[View](/fi/documents/scientific-conclusion/onsenal-epar-scientific-conclusion_fi.pdf)

svenska (SV) (300.06 KB - PDF)

**First published:**

15/11/2005

**Last updated:**

06/04/2011

[View](/sv/documents/scientific-conclusion/onsenal-epar-scientific-conclusion_sv.pdf)

## Initial marketing authorisation documents

Onsenal : EPAR - Procedural steps taken before authorisation

English (EN) (294.76 KB - PDF)

**First published:** 15/11/2005

**Last updated:** 06/04/2011

[View](/en/documents/procedural-steps/onsenal-epar-procedural-steps-taken-authorisation_en.pdf)

Onsenal : EPAR - Scientific Discussion

English (EN) (583.45 KB - PDF)

**First published:** 15/11/2005

**Last updated:** 06/04/2011

[View](/en/documents/scientific-discussion/onsenal-epar-scientific-discussion_en.pdf)

#### More information on Onsenal

This product was originally designated an [orphan medicine](/en/medicines/human/orphan-designations/eu-3-01-070) on 20 November 2001. Onsenal was withdrawn from the Community register of orphan medicinal products by the European Commission in March 2011 at the time of the withdrawal of the marketing authorisation.

**This page was last updated on** 06/04/2011

## Share this page

[Back to top](#main-content)